Carl Zeiss Meditec appears to be overvalued by 25% at the moment, based on our discounted cash flow valuation. The stock is currently priced at €70.85 on the market compared to our intrinsic value of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

I advocate international exposure selectively through individual stock ownership. Check out three European stocks that will ...

Carl Zeiss Meditec has seen a 30%+ decline due to earnings and margin drops, but remains a strong market leader with significant long-term upside. Despite current underperformance, the company's ...

The media outlet emphasizes that Carl Zeiss is a pioneering investor that found a place for its business in Belarus about 30 ...

With the KINEVO 900 S, ZEISS has raised the bar for state-of-the-art operating microscopes for neurosurgery." In 2017, the ...

Germany stocks were higher after the close on Friday, as gains in the Technology, Chemicals and Pharmaceuticals & Healthcare ...

Germany stocks were mixed after the close on Wednesday, as gains in the Retail, Food & Beverages and Consumer & Cyclical ...

In a report released on August 30, Oliver Reinberg from Kepler Capital maintained a Hold rating on Carl Zeiss Meditec (0DHC – Research Report), with a price target of €73.00. The company’s ...

It is part of SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Favorable industrywide trends, such as the aging population, an increasing prevalence of myopia, and a growing access to advanced healthcare across the globe, will act as tailwinds for Zeiss.